Scarica l'app Stockscreener
3.875
1.52%
-0.065
Precedente Chiudi:
$3.94
Aprire:
$3.79
Volume 24 ore:
80,242
Relative Volume:
0.48
Capitalizzazione di mercato:
$80.61M
Reddito:
-
Utile/perdita netta:
$-94.11M
Rapporto P/E:
-0.6448
EPS:
-6.01
Flusso di cassa netto:
$-86.06M
1 W Prestazione:
-15.84%
1M Prestazione:
-8.71%
6M Prestazione:
-48.47%
1 anno Prestazione:
-70.54%
Intervallo 1D:
$3.76
$4.01
Intervallo di 1 settimana:
$3.76
$4.755
Portata 52W:
$3.52
$13.40
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Nome
Adverum Biotechnologies Inc
Settore
Industria
Telefono
(650) 649-1004
Indirizzo
100 CARDINAL WAY, REDWOOD CITY, CA
Confronta ADVM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
3.86 | 80.61M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.81 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.50 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
559.07 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
244.92 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
239.78 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Aggiornamento | Truist | Hold → Buy |
| 2021-07-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | Downgrade | Truist | Buy → Hold |
| 2020-12-16 | Iniziato | UBS | Neutral |
| 2020-11-12 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-05 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-04-28 | Iniziato | Goldman | Buy |
| 2020-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-09-13 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-06-14 | Ripresa | Raymond James | Mkt Perform |
| 2018-11-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | Downgrade | SunTrust | Buy → Hold |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-30 | Iniziato | SunTrust | Buy |
| 2018-02-15 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Adverum Biotechnologies Inc Borsa (ADVM) Ultime notizie
Adverum biotechnologies sees $147k stock purchase by major shareholder - Investing.com Australia
Adverum Biotechnologies, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your RightsADVM - ACCESS Newswire
Adverum Biotechnologies Inc expected to post a loss of $1.36 a shareEarnings Preview - TradingView
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference - The Manila Times
Exclusive: Adverum Gene Therapy Updates Coming at Major Ophthalmology Conference - Stock Titan
Adverum biotechnologies investor Leonard Braden Michael buys $188,930 in stock By Investing.com - Investing.com Australia
Adverum biotechnologies sees insider purchase totaling $587,574 By Investing.com - Investing.com Canada
Adverum biotechnologies sees insider purchase totaling $587,574 - Investing.com
Adverum Biotechnologies (ADVM) to Release Earnings on Monday - Defense World
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD - Marketscreener.com
Adverum launches phase 3 trial for wet AMD gene therapy By Investing.com - Investing.com UK
Can This One-Time Gene Therapy Revolutionize Wet AMD Treatment? Adverum's Phase 3 Trial Begins - StockTitan
Adverum Biotechnologies initiates ARTEMIS study - TipRanks
Adverum biotechnologies sees $1.44 million stock purchase by major shareholder - Investing.com Australia
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How Adverum is Attracting Talent: New Employees Receive $186,000 in Equity Grants - StockTitan
Brokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Target Price at $27.83 - MarketBeat
Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference - The Manila Times
Gene Therapy Developer Adverum to Showcase Ocular Disease Pipeline at Major Healthcare Conference - StockTitan
Adverum Biotechnologies (NASDAQ:ADVM) Stock Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
3 US Penny Stocks With Market Caps Below $400M - Yahoo Finance
The Sonic Fund Solicits Proxies from Shareholders of Adverum Biotechnologies -April 13, 2021 at 04:16 pm EDT - Marketscreener.com
Adverum Biotechnologies (NASDAQ:ADVM) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
4D’s new data in wet AMD bolster its phase III study vision - BioWorld MedTech
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Gene Therapy Pioneer Adverum Takes Center Stage at Major Healthcare Conference - StockTitan
ADVM stock touches 52-week low at $4.01 amid market challenges - MSN
Brokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) PT at $27.83 - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $27.83 Average PT from Analysts - Defense World
Barclays PLC Buys 19,965 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Comparing Adverum Biotechnologies (NASDAQ:ADVM) & Pluri (NASDAQ:PLUR) - Defense World
Adverum Biotechnologies stock hits 52-week low at $4.4 - Investing.com
Adverum Biotechnologies stock hits 52-week low at $4.4 By Investing.com - Investing.com South Africa
Geode Capital Management LLC Sells 16,731 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Barclays PLC Purchases 19,965 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
State Street Corp Boosts Stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies Inc Azioni (ADVM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adverum Biotechnologies Inc Azioni (ADVM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner |
Apr 02 '25 |
Buy |
4.04 |
15,209 |
61,408 |
2,757,526 |
| Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
| Leonard Braden Michael | 10% Owner |
Mar 18 '25 |
Buy |
4.69 |
62,341 |
292,418 |
2,667,161 |
| Leonard Braden Michael | 10% Owner |
Mar 20 '25 |
Buy |
5.61 |
30,600 |
171,767 |
2,722,761 |
| Leonard Braden Michael | 10% Owner |
Mar 19 '25 |
Buy |
4.94 |
25,000 |
123,390 |
2,692,161 |
| Leonard Braden Michael | 10% Owner |
Feb 26 '25 |
Buy |
4.01 |
164,886 |
660,979 |
2,432,950 |
| Leonard Braden Michael | 10% Owner |
Feb 28 '25 |
Buy |
4.60 |
85,068 |
391,015 |
2,604,820 |
| Leonard Braden Michael | 10% Owner |
Feb 27 '25 |
Buy |
4.46 |
86,802 |
387,094 |
2,519,752 |
| Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
7.15 |
85,800 |
613,470 |
2,268,064 |
| Leonard Braden Michael | 10% Owner |
Jul 17 '24 |
Buy |
7.75 |
135,546 |
1,049,926 |
2,101,546 |
2.65%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):